Santen Wins South Korean Approval for Ryjusea Myopia Treatment

• Santen Pharmaceutical secured South Korean marketing approval for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution) to slow myopia progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santen Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.